Onderneming Glenmark Pharmaceuticals Limited
Aandelen
GLENMARK
INE935A01035
Farmaceutische producten
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1.079 INR | -0,09% | +5,16% | +26,39% |
25/04 | Nettowinst Glenmark Lifesciences daalt in fiscaal vierde kwartaal | MT |
01/04 | Glenmark Pharmaceuticals Limited kondigt bestuurswisselingen aan | CI |
Vakgebied
Aantal werknemers: 15 556
Verkoop per activiteit
INR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100,0
%
| 123 049 | 100,0 % | 129 901 | 100,0 % | +5,57% |
Verkoop per regio
INR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
India
34,4
%
| 43 809 | 35,6 % | 44 675 | 34,4 % | +1,98% |
North America
25,0
%
| 32 035 | 26,0 % | 32 484 | 25,0 % | +1,40% |
Europe
17,7
%
| 20 047 | 16,3 % | 23 047 | 17,7 % | +14,97% |
Rest of the World
17,3
%
| 21 031 | 17,1 % | 22 414 | 17,3 % | +6,58% |
Latin America
5,6
%
| 6 127 | 5,0 % | 7 281 | 5,6 % | +18,83% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | - | - | |
Chief Executive Officer | 54 | 12-10-98 | |
Ulhas Dhuppad
PSD | President | - | - |
Alind Sharma
PSD | President | - | 01-06-22 |
V. S. Mani
DFI | Director of Finance/CFO | 59 | 16-11-17 |
Nikhil Amin
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | - | |
Harish Kuber
CMP | Compliance Officer | - | 02-02-17 |
Rajesh V. Desai
BRD | Director/Board Member | 65 | 01-01-83 |
Cherylann Pinto
BRD | Director/Board Member | 56 | 06-10-99 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 59 | 14-08-20 | |
Cherylann Pinto
BRD | Director/Board Member | 56 | 06-10-99 |
Chief Executive Officer | 54 | 12-10-98 | |
Rajesh V. Desai
BRD | Director/Board Member | 65 | 01-01-83 |
Director/Board Member | 83 | 14-08-09 | |
Director/Board Member | 68 | 10-02-23 | |
Director/Board Member | 48 | 01-04-19 | |
V. S. Mani
DFI | Director of Finance/CFO | 59 | 16-11-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 282 188 156 | 138 368 096 ( 49,03 %) | 0 | 49,03 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
9 609 571 | 7.84% | 89 329 419 $ |
Bedrijfsgegevens
Glenmark Pharmaceuticals Ltd.
Glenmark House Off Western Express Highway
400099, Mumbai
+91 22 4018 9999
http://www.glenmarkpharma.comBedrijven van de groep
Naam | Categorie en sector |
---|---|
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Glenmark Pharmaceuticals USA, Inc. manufactures, markets, and distributes generic pharmaceutical products. It offers campral delayed-release tablets, differin gel, aclovate cream, aclovate topical ointment, ortho novum, and other related products. The company was founded in 2003 and is headquartered in Mahwah, NJ. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Sector
Verkoop per regio
Herzieningen van WPA
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,39% | 3,66 mld. | |
+20,44% | 21,89 mld. | |
+10,31% | 14,45 mld. | |
+13,07% | 13,63 mld. | |
+37,46% | 11,49 mld. | |
-8,59% | 6,85 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+6,35% | 5,06 mld. | |
-5,36% | 4,66 mld. |
- Beurs
- Aandelen
- Koers GLENMARK
- Onderneming Glenmark Pharmaceuticals Limited